ストックスクリーナーアプリを入手
9.57
2.94%
-0.29
Turn Therapeutics Inc (TTRX) 最新ニュース
Ladenburg Thalmann Initiates Turn Therapeutics(TTRX.US) With Buy Rating, Announces Target Price $16 - Moomoo
Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5%Time to Sell? - marketbeat.com
Turn Therapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Long-Term Debt - Kalkine Media
Form 8K Turn Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Turn Therapeutics (NASDAQ: TTRX) posts larger loss, adds debt and warns on going concern - Stock Titan
Turn Therapeutics Q2 net loss per share widens on higher R&D costs - TradingView
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Turn Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Turn Therapeutics Rings the Closing Bell - Nasdaq
Turn Therapeutics Ord Shs (TTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to sales forward of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics Inc. Revenue Breakdown – NASDAQ:TTRX - TradingView
Turn Therapeutics Updates GX-03 Investor Presentation and Pipeline - TipRanks
Turn updates investor presentation, cites Q4 2026 AD Phase 2 topline and $11.2M cash - TradingView
GX-03 trial data and cash runway at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 - Business Wire
Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TTRX|Turn Therapeutics Ord Shs|Price:9.575|Chg%:+0.735 - TradingKey
TTRX Forecast — Price Target — Prediction for 2027 - TradingView
Turn Therapeutics Inc. Common Stock (NASDAQ: TTRX) Stock Price, News & Analysis - Kalkine
Zacks Research Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold - MarketBeat
Enterprise value to revenue forward of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Subscribers: Disregard Turn Therapeutics Shares Rise Article - Moomoo
LADENBURG THALM/SH SH Upgrades Turn Therapeutics (NASDAQ:TTRX) to Strong-Buy - MarketBeat
Turn Therapeutics Shares Rise on Expanded Phase 2 Study For Eczema Treatment - Moomoo
Ladenburg Thalmann Initiates Turn Therapeutics at Buy With $26 Price Target - Moomoo
Why is Turn Therapeutics stock trading higher today? - MSN
Turn Therapeutics (NASDAQ:TTRX) Upgraded by Wall Street Zen to "Hold" Rating - marketbeat.com
Turn Therapeutics (TTRX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Turn Therapeutics (TTRX) Q4 2025 earnings summary - Quartr
Turn Therapeutics (TTRX) Corporate presentation Summary - Quartr
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - AOL.com
Turn Therapeutics: Small Market Cap, Huge Potential (NASDAQ:TTRX) - Seeking Alpha
Enterprise value to EBIT forward of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics Inc.Common Stock (TTRX) Stock Price, News, Quote & History - FinancialContent
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout - sharewise.com
Turn Therapeutics’ stock jumps on AD data and trial expansion - MSN
Turn Therapeutics (TTRX) Open Investor Session materials presentation Summary - Quartr
Turn Therapeutics Reaches US$229m Market Cap Benefiting Insider Stock Buying - 富途牛牛
Turn Therapeutics (TTRX) Study update Summary - Quartr
TTRX: GX-03 phase II interim data show robust efficacy and safety, with stage two now optimized - TradingView
TTRX: GX-03 phase II interim data show strong efficacy and safety, with phase III targeted for mid-2027 - TradingView
Why Is Turn Therapeutics Stock Trading Higher Today? - Benzinga
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - AOL.com
AD Pipeline Watch: Turn Therapeutics Expands Phase 2 AD Trial After GX-03 Shows Broad Efficacy in Interim Analysis - The Dermatology Digest
TTRX: GX-03 demonstrates robust efficacy and safety in Phase 2 atopic dermatitis interim analysis - TradingView
TTRX: GX-03 showed robust efficacy in atopic dermatitis, leading to an expanded Phase 2 trial design - TradingView
Turn Therapeutics stock rises on expanded dermatitis trial By Investing.com - Investing.com Nigeria
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - BioSpace
Turn Therapeutics stock rises on expanded dermatitis trial - Investing.com
Turn Therapeutics expands phase 2 atopic dermatitis trial - Investing.com
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis - marketscreener.com
Turn Therapeutics expands phase 2 atopic dermatitis trial By Investing.com - Investing.com Nigeria
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):